Intestinal Microbiota Transplantation for Nonalcoholic Fatty Liver Disease

Non-alcoholic Fatty Liver Disease Clinical Trial

— NAFLD  

Official title:

Efficacy, Safety of Intestinal Microbiota Transplantation for Nonalcoholic Fatty Liver Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03648086
• Other study ID #: 2017005
• Status: Recruiting
• Phase: N/A
• Start date: November 14, 2017
• Est. completion date: November 2020

Study information

• Verified date: October 2017
• Source: Zhongshan Hospital Xiamen University
• Contact: Yang Song
• Phone: 18559666260
• Email: tcsongyang[@]sina.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In China, with the improvement of living standards, there is a significant increase in the rate of prevalence of type 2 diabetes and hyperlipidemia, associated with Non-alcoholic fatty liver disease（NAFLD） which has gradually become a major public health problem in our country. The latest study found that intestinal microflora imbalance is closely correlated with NAFLD. In this subject, the investigators aim to explore whether intestinal microbiota transplantation(IMT) could reverse the change of intestinal microflora imbalance and has direct effects of NAFLD.

Description:

Non-alcoholic fatty liver disease (NAFLD) is a significant health problem. With the trend of obesity and associated metabolic syndrome globally, nonalcoholic fatty liver disease has become a high incidence of liver disease in developed countries, the prevalence rate of NAFLD adult is about 10% ~ 30%. Therefore, effective prevention and treatment of NAFLD has important significance in improving people's quality of life and disease prognosis. The latest study found that intestinal microflora imbalance is closely correlated with NAFLD. When the structure of intestinal flora is destroyed, host energy absorption and storage of fat balance will be broken, with higher absorption of efficiency. At the same time, metabolic disorder expands. In this projects the investigators aim to re-establish a gut balance of intestinal microbiota through Standardized Intestinal Microbiota Transplantation for NAFLD. The CT ratio of liver/spleen, Fibroscan E value, general indicators, biochemical indicators will be used to assess the efficiency, durability and safety of Standardized IMT at the start and end of the projects.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: November 2020
• Est. primary completion date: October 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• subjects with NAFLD(nonalcoholic fatty liver disease)

• aged 18-65

• 24=BMI

• liver/spleen (L/S) ratio no more than 0.7 by CT scan

Exclusion Criteria:

• Alcoholic liver disease (ALD), chronic hepatitis C, autoimmune liver disease, Wilson's disease

• Drug treatment (tamoxifen, amiodarone, sodium valproate, methotrexate, glucocorticoids, etc.), total parenteral nutrition, inflammatory bowel disease, hypothyroidism, Cushing's syndrome, beta lipoprotein deficiency, IR related syndromes (lipid wasting diabetes mellitus, Mauriac syndrome), gastrointestinal surgery

• Hepatocellular carcinoma (HCC), biliary tract diseases and taking or taking chinese and western medicines that can lead liver enzymes elevation in the near future.

• Moderate and severe renal injuty(serum creatinine>2mg/dL or 177mmol/L), moderate and severe chronic obstructive pulmonary disease, severe hypertension, cerebrovascular accident, congestive heart failure, unstable angina pectoris.

• Antibiotics treatment in 7 days before recruited and unwilling to stop it, long-term lipid-lowering drugs, antidiabetic drugs and other liver protecting drugs treatment

• Antibiotics, other probiotics, gastrointestinal motility drugs and other preparation that may influence intestinal microbiota treatment

• Other serious diseases that may interfere the recruitment or affect the survival, such as cancer or acquired immune deficiency syndrome

• Mentally or legally disabled person

• Preparing for pregnancy

• Medical or social condition which in the opinion of the principal investigator would interfere with or prevent regular follow up

• Participating in other clinical trials.

Related Conditions & MeSH terms

• Fatty Liver
• Liver Diseases
• Non-alcoholic Fatty Liver Disease

Intervention

Other:
• intestinal microbiota transplantation
Participants in Exprerimental group take 6 times IMT with 2-week intervals

Locations

Country	Name	City	State
China	Zhongshan Hospital Affiliated to Xiamen University	Xiamen	Fujian

Sponsors (1)

Lead Sponsor	Collaborator
Zhongshan Hospital Xiamen University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The change of CT ratio of liver/spleen	CT imaging has been used to assess hepatic steatosis and has been validated in relation to liver biopsy .The ratio of liver to spleen (L/S ratio) for CT attenuation values is an index, with a L/S ratio<1 considered to represent fatty liver .The change of CT ratio of liver/spleen will be assessed at different time comparing with the baseline.	3 months, 6months
Secondary	biochemical indicators	Liver function such as ALT,AST,ALT/AST will be assessed at different time comparing with the baseline.	3 months, 6months
Secondary	Fibroscan E value	Fibroscan E value is a indicators for evaluating liver fibrosis.Changes will be assessed at different time comparing with the baseline.	3 months, 6 months
Secondary	Changes of gut microbiota	Alpha and Beta diversity of GI microbiota by High-throughput sequencing on baseline line and 3 months, 6months after treatment	3 months, 6months